BioMarin Pharmaceutical Inc. (BMRN)
After hours:
| Previous close | 82.44 |
| Open | 83.20 |
| Bid | 82.09 x 400 |
| Ask | 82.16 x 400 |
| Day's range | 81.83 - 83.58 |
| 52-week range | 76.02 - 99.56 |
| Volume | |
| Avg. volume | 1,578,145 |
| Market cap | 15.589B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 77.45 |
| EPS (TTM) | 1.06 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 110.10 |
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
PR NewswireNew Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
Simply Wall St.BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its first-quarter result to...
